摘要
目的探讨PCI术后氯吡格雷弱代谢患者改服替格瑞洛的可行性与安全性。方法以2016年2月至2016年12月在我院心内科行PCI术后存在氯吡格雷弱代谢的患者142例为研究对象,随机分成观察组(n=71)与对照组(n=71)。两组测定均存在氯吡格雷弱代谢,观察组患者改服替格瑞洛治疗,对照组患者继续服用氯吡格雷治疗。两组患者治疗3 d后检查血栓弹力图,同时评价血小板抑制率。维持半年随访时间,观察两组患者不良心血管事件(MACE)与出血事件发生率。结果经3 d治疗,观察组ADP抑制率明显高于治疗前及对照组,血小板—纤维蛋白凝块强度(MAADP)低于治疗前及对照组(P<0.05)。两组患者不良事件发生率比较,差异无统计学意义(P>0.05)。随访结果显示两组均未出现严重出血或心血管死亡事件。结论PCI术后氯吡格雷弱代谢患者改服替格瑞洛治疗效果显著,起效快,可明显抑制血小板,并发症发生率低。
Objective To observe the clinical feasibility and safty of ticagrelor in the treatment of poor metabolism of clopidogrel after PCI surgery. Methods A total of 142 patients with poor metabolism of clopidogrel who underwent PCT in the cardiology department of our hospital from February 2016 to December 2016 were enrolled in this study, and randomly divided into observation group and control group, with 71 cases in each group. The poor metabolism of clopidogrel was detected in both groups, the patients in the observation group switched to ticagrelor, and the patients in the control group continued taking clopidogrel. After the treatment for 3 days, the thromboelastography, the platelet inhibition rate were reviewed; after 6 months follow-up, major adverse cardiovascular events（MACE） and bleeding were observed in the two groups. Results After the treatment for 3 days, the inhition rate of ADP in the observation group was signifycantly higher than that before treatment and the control group, and the MAADP was lower than that before treatment and the control group（P0.05）. The incidence rates of adverse events in the two groups showed no significant difference（P0.05）. There was no serious bleeding events and cardiovascular deaths during the follow-up. Conclusion Ticagrelor applied in patients with poor metabolism of clopidogrel after PCI surgery has rapid onset and good anti-platelet effect, it can singnificantly inhibit the platelet, which has little serious complications.
出处
《临床医学研究与实践》
2018年第5期9-10,共2页
Clinical Research and Practice
